Literature DB >> 29674342

APP deficiency results in resistance to obesity but impairs glucose tolerance upon high fat feeding.

Juliane K Czeczor1, Amanda J Genders1, Kathryn Aston-Mourney1, Timothy Connor1, Liam G Hall1, Kyoko Hasebe1, Megan Ellis1, Kirstie A De Jong1, Darren C Henstridge2, Peter J Meikle2, Mark A Febbraio3, Ken Walder1, Sean L McGee4,2.   

Abstract

The amyloid precursor protein (APP) generates a number of peptides when processed through different cleavage mechanisms, including the amyloid beta peptide that is implicated in the development of Alzheimer's disease. It is well established that APP via its cleaved peptides regulates aspects of neuronal metabolism. Emerging evidence suggests that amyloidogenic processing of APP can lead to altered systemic metabolism, similar to that observed in metabolic disease states. In the present study, we investigated the effect of APP deficiency on obesity-induced alterations in systemic metabolism. Compared with WT littermates, APP-deficient mice were resistant to diet-induced obesity, which was linked to higher energy expenditure and lipid oxidation throughout the dark phase and was associated with increased spontaneous physical activity. Consistent with this lean phenotype, APP-deficient mice fed a high-fat diet (HFD) had normal insulin tolerance. However, despite normal insulin action, these mice were glucose intolerant, similar to WT mice fed a HFD. This was associated with reduced plasma insulin in the early phase of the glucose tolerance test. Analysis of the pancreas showed that APP was required to maintain normal islet and β-cell mass under high fat feeding conditions. These studies show that, in addition to regulating aspects of neuronal metabolism, APP is an important regulator of whole body energy expenditure and glucose homeostasis under high fat feeding conditions.
© 2018 Society for Endocrinology.

Entities:  

Keywords:  amyloid precursor protein; energy expenditure; glucose metabolism; insulin secretion; obesity

Mesh:

Substances:

Year:  2018        PMID: 29674342     DOI: 10.1530/JOE-18-0051

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  5 in total

1.  Ablation of amyloid precursor protein increases insulin-degrading enzyme levels and activity in brain and peripheral tissues.

Authors:  Joshua A Kulas; Whitney F Franklin; Nicholas A Smith; Gunjan D Manocha; Kendra L Puig; Kumi Nagamoto-Combs; Rachel D Hendrix; Giulio Taglialatela; Steven W Barger; Colin K Combs
Journal:  Am J Physiol Endocrinol Metab       Date:  2018-11-13       Impact factor: 4.310

Review 2.  The amyloid precursor protein: a converging point in Alzheimer's disease.

Authors:  Alexandré Delport; Raymond Hewer
Journal:  Mol Neurobiol       Date:  2022-05-17       Impact factor: 5.590

3.  Dysregulation of Amyloid Precursor Protein Impairs Adipose Tissue Mitochondrial Function and Promotes Obesity.

Authors:  Yu A An; Clair Crewe; Ingrid Wernstedt Asterholm; Kai Sun; Shiuhwei Chen; Fang Zhang; Mengle Shao; Jan-Bernd Funcke; Zhuzhen Zhang; Leon Straub; Jun Yoshino; Samuel Klein; Christine M Kusminski; Philipp E Scherer
Journal:  Nat Metab       Date:  2019-12-13

4.  Loss of protein kinase D activity demonstrates redundancy in cardiac glucose metabolism and preserves cardiac function in obesity.

Authors:  Kirstie A De Jong; Liam G Hall; Mark C Renton; Timothy Connor; Sheree D Martin; Greg M Kowalski; Christopher S Shaw; Clinton R Bruce; Kirsten F Howlett; Sean L McGee
Journal:  Mol Metab       Date:  2020-10-21       Impact factor: 7.422

5.  Regulation of PPARα by APP in Alzheimer disease affects the pharmacological modulation of synaptic activity.

Authors:  Francisco Sáez-Orellana; Thomas Leroy; Floriane Ribeiro; Anna Kreis; Karelle Leroy; Fanny Lalloyer; Eric Baugé; Bart Staels; Charles Duyckaerts; Jean-Pierre Brion; Philippe Gailly; Jean-Noël Octave; Nathalie Pierrot
Journal:  JCI Insight       Date:  2021-08-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.